Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMSW) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for NewAmsterdam Pharma (NAMSW) over the last 4 years, with Q3 2025 value amounting to $786.4 million.

  • NewAmsterdam Pharma's Liabilities and Shareholders Equity rose 7906.26% to $786.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 9080.36%. This contributed to the annual value of $864.6 million for FY2024, which is 14910.04% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Liabilities and Shareholders Equity is $786.4 million, which was up 7906.26% from $815.1 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma's Liabilities and Shareholders Equity peaked at $864.6 million during Q4 2024, and registered a low of $347.1 million during Q4 2023.
  • Its 4-year average for Liabilities and Shareholders Equity is $606.1 million, with a median of $527.7 million in 2022.
  • In the last 5 years, NewAmsterdam Pharma's Liabilities and Shareholders Equity plummeted by 3600.08% in 2023 and then soared by 14910.04% in 2024.
  • Quarter analysis of 4 years shows NewAmsterdam Pharma's Liabilities and Shareholders Equity stood at $542.3 million in 2022, then tumbled by 36.0% to $347.1 million in 2023, then soared by 149.1% to $864.6 million in 2024, then fell by 9.04% to $786.4 million in 2025.
  • Its Liabilities and Shareholders Equity was $786.4 million in Q3 2025, compared to $815.1 million in Q2 2025 and $818.4 million in Q1 2025.